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Abstract 50 
Purpose: To characterise the molecular mechanism underpinning early-onset macular drusen 51 
(EOMD), a phenotypically severe sub-type of age-related macular degeneration (AMD), in a sub-52 
group of patients. 53 
Design: Multi-centre case series, in vitro experimentation and retrospective analysis of previously 54 
reported variants. 55 
Participants: Seven families with apparently autosomal dominant EOMD. 56 
Methods:  Patients underwent comprehensive ophthalmic assessment.  Affected individuals from 57 
families A, B and E underwent whole exome sequencing.  The probands from families C, D, F and G 58 
underwent Sanger sequencing analysis of the Complement Factor H (CFH) gene.  Mutant 59 
recombinant Factor H Like-1 (FHL-1) proteins were expressed in HEK293 cells to assess the impact on 60 
FHL-1 expression and function.  Previously reported EOMD-causing variants in CFH were reviewed. 61 
Main Outcome Measures: Detailed clinical phenotypes, genomic findings, in vitro characterization of 62 
mutation effect on protein function, and postulation of the pathomechanism underpinning EOMD. 63 
Results: All affected participants presented with bilateral drusen.  The earliest reported age of onset 64 
was 16 years  with a median of 46 years).  Ultra-rare (MAF ≤0.0001) CFH variants were identified as 65 
the cause of disease in each family:  CFH c.1243del, p.(Ala415ProfsTer39) het; c.350+1G>T het; 66 
c.619+1G>A het, c.380G>A, p.(Arg127His) het; c.694C>T p.(Arg232Ter)het [identified in two 67 
unrelated families in this cohort];  and c.1291T>A, p.(Cys431Ser).  All mutations affect complement 68 
control protein domains (CCP) 2-7, thus are predicted to impact both FHL-1, the predominant 69 
isoform in Bruch’s membrane(BrM) of the macula, and FH.  In vitro analysis of recombinant proteins 70 
FHL-1R127H, FHL-1A415f/s and FHL-1C431S demonstrated that they are not secreted and thus are loss-of-71 
function.  Intra-cellular expression of mutant proteins was low, suggesting they may be rapidly 72 















mutations found that 75.8% (22/29) of impact FHL-1 and FH.  In total, 86.2% (25/29) EOMD-74 
associated variants cause haploinsufficiency of FH/FHL-1. 75 
Conclusions:  EOMD is an under-recognised, phenotypically severe sub-type of AMD.  We propose 76 
that haploinsufficiency of FHL-1, the main regulator of the complement pathway in BrM, where 77 
drusen develop, is an important mechanism underpinning the development of EOMD in a number of 78 
cases.  Understanding the molecular basis of EOMD will shed light on AMD pathogenesis given their 79 
pathological similarities. 80 
Key words: early onset macular drusen, age-related macular degeneration, complement factor-H, 81 
CFH, FHL-1 82 
Introduction 83 
Age-related macular degeneration (AMD) represents a leading cause of irreversible vision loss, 84 
accounting for 8.7% of global blindness 
1
. The condition is characterised by inflammation and the 85 
deposition of extracellular material in the form of drusen, in Bruch’s membrane (BrM).  Drusen can 86 
cause metabolic disruption that leads to dysfunction and death of retinal pigment epithelium (RPE).  87 
Later stages of AMD may be characterised by geographic atrophy or choroidal neovascularisation, 88 
these are associated with severe loss of central vision.  It is now widely accepted that an excessive 89 
inflammatory response driven by inadequate regulation of the complement cascade is a major 90 
contributory factor to AMD 
2
. AMD is a disease of multifactorial aetiology with a strong genetic 91 
component and the role of the complement pathway in AMD pathogenesis is corroborated by the 92 
implication of genetic variants in a number of complement factors with AMD risk 
3, 4
. Genetic 93 
variants associated with AMD represent a broad allelic range, from common polymorphisms (minor 94 
allele frequency (MAF) >1%) that confer a relatively low risk of disease 
5-9
, to relatively rare variants 95 
(MAF<1%) that demonstrate high penetrance, e.g. the p.(Arg1210Cys) substitution in CFH 
10
.  96 
The complement system is a crucial component of host innate immunity 
11
.  It is a cascade system 97 















uniquely, but which converge upon three common goals: modifying the membrane of an unwanted 99 
cell for phagocyte recognition, generation of membrane attack complexes for cell lysis, and 100 
promoting an inflammatory response
2
.  Complement can activate on all surfaces, both host or 101 
foreign, so the host requires mechanisms to prevent inappropriate self-directed damage 
12
.  The 102 
alternative pathway (AP) is constantly active at a low level and contains a positive feedback loop to 103 
allow rapid amplification of the complement response.  Tight regulation is required to maintain 104 
balanced immune homeostasis and it is increasingly recognised that defective regulation of the AP 105 
plays a central role in human disease 
13, 14
. 106 
The complement factor H (CFH) gene encodes a 155 kDa plasma protein known as Factor H (FH)
15
 107 
that functions as a complement regulator by binding to host surfaces to protect them against 108 
complement activation.  It mainly exerts its effect on the AP pathway, negatively regulating the 109 
positive feedback loop.  FH harbours 20 complement control protein (CCP) domains, each 110 
comprising 60 amino acids, that can be grouped into three functional domains, CCP 1-4 form a 111 
binding site for co-factor activity; while both CCP 6-8 and CCP19-20 facilitate binding of FH via 112 
glycoaminoglycans (GAGs) to cell surfaces and extracellular matrices (ECM) 
2, 16
.   113 
Disease-causing variants in CFH result in three distinct pathological syndromes: atypical haemolytic 114 
uraemic syndrome (aHUS), C3 glomerulopathy (C3G; a clinical entity that encompasses C3 115 
glomerulonephritis and dense deposit disease (DDD) -formerly membranoproliferative 116 
glomerulonephronophthitis type II or MPGN II), and AMD.  An apparent genotype-phenotype 117 
correlation exists whereby the majority of aHUS-causing variants affect CCP19 and CCP20 
17
, whilst 118 
variants associated with AMD predominantly affect CCPs 1-4, and 6-8 
18, 19
.  In 2008, Boon et al., and 119 
then van de Ven et al. in 2012, showed that an early-onset sub-type of AMD was caused by 120 
monogenic inheritance of ultra-rare variants in CFH 
20, 21
.  This AMD sub-type (which for clarity we 121 
term ‘early-onset macular drusen’ (EOMD)) demonstrates much earlier age of onset (mean age = 50 122 
years), causing many more years of substantial visual loss than AMD 
20, 21
.  There have since been 123 

















Alternative splicing of CFH exon 9 produces a variant of FH known as factor H-like 1 (FHL-1) that is 125 
identical to CCPs 1-7 of FH, has a unique carboxy-terminal tail of four amino acids, and is significantly 126 
smaller (49kDa).  Recent work has suggested that FHL-1 retains the same regulatory functions as FH 127 
and is able to bind to surfaces via its single GAG-interaction domain at CCPs 6-7 to regulate the 128 
complement cascade 
26
.  Impaired FH and FHL-1 function leads to disease as a result of inflammation 129 
and cellular debris mishandling due to excessive AP activation driven by defective regulation of the 130 
complement cascade 
2, 26
. Genetic studies of AMD fail to distinguish between FH and FHL-1.  FHL-1 is 131 
the major isoform present within BrM of the retina 
26, 27
, a major site of AMD pathogenesis and 132 
where drusen, the characteristic lesions of AMD, form.  It has been suggested that it is this isoform 133 
that protects BrM against complement activation 
26
.  134 
Herein, we perform functional and variant localization analysis of the EOMD-causing variants that lie 135 
within FHL-1 and define the mechanism responsible for one subgroup of patients affected by this 136 
phenotypically severe condition.   137 
Methods  138 
Ethics and Patient Recruitment 139 
Ethics committee approval was obtained from the North West Regional Ethics Committee for all 140 
aspects of this study (15/YH/0365) and the protocol observed the tenets of the Declaration of 141 
Helsinki.  Written informed consent was obtained from each study participant as an essential pre-142 
requisite for study inclusion.  Patients with early-onset macular drusen (EOMD) were included in our 143 
analysis.  Given the heterogeneous nature of drusen and to limit bias, we did not select patients 144 
based on the type/size of drusen they presented with.   145 
Clinical Assessment 146 
Each patient underwent full ophthalmic assessment including visual acuity and dilated fundus 147 
examination.  Fundus photographs were obtained using Ultra-Widefield Optos™ colour fundus 148 
imaging (Optos plc, Dunfermlin, UK).  Fundus autofluorescence (FAF) imaging was conducted using 149 
either the Spectralis (Heidelberg Engineering Ltd., Heidelberg, Germany) or ultra-widefield confocal 150 















performed using the Spectralis OCT platform (Heidelberg Engineering).  Electroretinography (ERG) 152 
was performed to standards specified by the International Society for Clinical Electrophysiology of 153 
Vision (ISCEV).  Clinical history was also obtained to discern the presence of additional health 154 
problems. 155 
Whole-exome sequencing 156 
Whole-exome sequencing (WES), performed as previously published
28
, was carried out as part of an 157 
ongoing study on inherited retinal disease (UK Inherited Retinal Dystrophy Consortium, UKIRDC) in 158 
families without a molecular diagnosis following NGS screening for a panel of 105 or 176 genes 159 
known to cause inherited retinal dystrophy. Detailed methodology can be found in Supplementary 160 
Data A (available at www.aaojournal.org).  WES data from affected relatives (A:II.1 and A:II.3; E:III.11 161 
and  E:II.8) was analysed for shared rare variants.  Variants in genes known to be involved in IRD 162 
were examined as a priority.  Identified variants were interpreted according to the Association for 163 
Clinical Genetic Science Best Practice Guidelines for Variant Classification 2018. 164 
Sanger sequencing of CFH 165 
Seventy-five patients diagnosed with dominant/early drusen who tested negative for the EFEMP1 166 
c.1033C>T; p.(Arg345Trp) variant were retrospectively identified from a referrals database and were 167 
subjected to screening for variants in the CFH gene by Sanger sequencing.  The coding exons and 168 
flanking intronic sequences of CFH (NM_000186) plus an additional four amino acids unique to the 169 
alternative transcript, FHL-1 (exon 10, NM_0010149975) were amplified by PCR and subject to bi-170 
directional Sanger sequencing (see supplementary data A, available at www.aaojournal.org,for 171 
details).  Variants were interpreted as before (see ‘whole exome sequencing’). 172 
Functional Characterization of Genetic Variants 173 
N-terminal His-tagged, DNA sequences encoding human FHL-1 or mutant versions of FHL-1, were 174 
synthesized and inserted in to pcDNA3.1 by GeneArt (Invitrogen).  Plasmid DNA was stably 175 
transfected in to HEK293 cells using polyethylenimine (PEI) and culture media was harvested from 176 
transfected cells at 24, 48, 72, and 144 hours.  His-tagged recombinant proteins were purified from 177 















chromatography.  Cell lysates were made from transfected HEK293 cells and quantified using the 179 
Pierce BCA protein assay.  Western blotting was conducted as previously described
26
.  Detailed 180 
methodologies for plasmid preparation, transformation and transfection, purification of 181 
recombinant proteins and Western blotting can be found in Supplementary Data A (available at 182 
www.aaojournal.org). 183 
Results 184 
Retinal Findings 185 
We report ten individuals from seven unrelated families with a monogenic form of early-onset 186 
macular drusen (Figure 1 available at www.aaojournal.org).  Retinal phenotypes are summarised 187 
below and in Table 1.  Detailed ophthalmic histories for each case can be found in Supplementary 188 
data A (available at www.aaojournal.org).  None of the individuals included in this study had 189 
evidence of renal disease. The median age of drusen onset was 46 years The average age at onset in 190 
our cohort is skewed by late identification of disease in individual B:II.2 who did not receive a 191 
diagnosis until 80 years of age. The earliest documented age at which drusen were identified was 16 192 
years in individual A:II.1, younger than has previously been reported in EOMD.  In all affected study 193 
participants, drusen were bilateral and broadly symmetrical, and visible on fundus 194 
examination/colour photos (Figure 2, available at www.aaojournal.org), fundus autofluorescence 195 
(FAF) (Figure 3) and/or optical coherence tomography (OCT) (Figure 4, available at 196 
www.aaojournal.org).   The impact on visual acuity was varied, from no apparent impact (B:I.1), to 197 
mild (A:II.3, A:II.1, C:I.2, D:I.7, E:III.11, F:II.2, G:III.7), moderate (D:II:2, E:II.2),  and severe visual loss 198 
(B:II.2).  As shown in Figure 2-4, varying phenotypes and degrees of disease severity were present in 199 
study participants.  This is possibly reflective of the fact that individuals in our cohort are a range of 200 
ages and thus represent various disease stages.  However, in younger participants, we cannot rule 201 
out non-progressive disease, at this time. 202 
In family A, both affected siblings presented with small drusen, scattered throughout the retina in an 203 















examination of their mother found that she was unaffected.  Proband B:I.1  from family B, was found 205 
to have multiple small drusen at the macula and nasal to the optic discs.  His mother, B:II.2, was 206 
more advanced, showing drusen as well as atrophy at both the macula and the nasal retina.  C:I.1, 207 
presented with central scotomata, and drusen surrounding a region of central atrophy that extended 208 
to the vascular arcades.  She had patchy atrophy with reticular and drusenoid features in the retinal 209 
periphery with mid-peripheral sparing.  Her mother and sister had also received a diagnosis of 210 
macular drusen.  The proband from family D (D:I.7) presented with multiple large drusen bilaterally, 211 
associated with atrophy of the right macula.  Her affected father (D:II.2) presented with advanced 212 
neovascular macular degeneration.  Family history revealed the proband’s paternal aunt (D:II.1) and 213 
great grandfather (D.IV.6) had experienced visual deterioration in their forties.  It was also noted 214 
that her paternal great aunt (D.IV.2) and great uncle (D:IV.5) were affected in their fifties, although 215 
no further information was available.  Her paternal grandmother (D:III.3) was deceased aged 56 216 
years and it is not known whether she was also affected.  The proband from family E (E:III.11) 217 
presented with central vision problems.  FAF revealed hypoautofluorescence centrally due to 218 
geographic atrophy with a surrounding ring of hyperautofluorescence and drusen nasal to the optic 219 
disc.  Pigmentary changes and drusen were also seen in the peripheral retina.  Her affected son 220 
(E:II.8) was found to have small, sparse macular drusen at the age of 40 years. Family history 221 
revealed multiple affected members in family E.  Fundoscopy of the proband from family F (F:II.2) 222 
revealed isolated sparse drusen within the temporal macula.  At the time of her diagnosis, her 223 
mother (F:III.2) was being treated for choroidal neovascularisation.  Proband G:III.7 from family G 224 
presented with clustered drusen spread throughout the macula, with early non-foveal geographic 225 
atrophy in the left eye.  Her sister (G:III.3) and two brothers (G:III.1 and G.III.4) were also affected.  226 
Her mother died aged 30 years and her father died aged 80 with no known visual problems. 227 
Genetic Findings 228 
The proband from families A, B, and E underwent testing for variants in the coding and flanking 229 















associated with macular drusen (ABCA4: NM_000350; CA4: NM_000717; CNGB3: NM_019098; 231 
EFEMP1: NM_001039348; PROM1: NM_006017; TIMP3: NM_000362).  No putative disease-causing 232 
or carrier variants were identified.  Subsequently, each was recruited to the UKIRDC study and WES 233 
was conducted on DNA from the affected sibling pair of family A (A:II.1 and A:II.3), the proband of 234 
family B (B:II.2), and the affected mother (E.II.2) and son (E.I.1) of family E.  In each family, an ultra-235 
rare (MAF<0.01%) or novel heterozygous CFH variant was identified as the probable cause of disease 236 
(Table 1).  NGS analysis and interpretation of variants can be found in Supplementary Data F 237 
(available at www.aaojournal.org).   238 
A cohort of 75 patients diagnosed with macular drusen, and negative for the EFEMP1 c.1033C>T 239 
p.(Arg345Trp) variant, were screened for variants in the coding and flanking intron regions of the 240 
CFH gene (NM_000186) including an alternatively encoded exon from the transcript 241 
NM_0010149975. Four patients (the probands of families C,D, F, and G: C:I.2, D:I.7, F:II.2, G:III.7) 242 
were found to harbour novel or ultra-rare (MAF<0.01%) heterozygous variants in the CFH gene 243 
(Table 1).   244 
In total, six different CFH variants were identified in seven EOMD families (Table 1).  Segregation 245 
analysis was performed where possible and the respective variant segregated with disease in each 246 
case (family members tested, their disease status and their genetic status are indicated in 247 
Supplementary Data B, available at www.aaojournal.org).  Three mutations, which have not 248 
previously been reported in association with disease, represent novel EOMD-causing mutations: CFH 249 
c.1243del, p.(Ala415ProfsTer39) het; CFH c.350+1G>T het; and CFH c.619+1G>A het.  The three 250 




; CFH c.694C>T, p.(Arg232Ter)
30
 identified in two unrelated families in this cohort;  and CFH 252 






All six mutations identified in this study affect complement control protein (CCP) domains 2-7 (Table 255 















Functional characterization of CFH mutations in Recombinant FHL-1 257 
Previous studies have shown that rare CFH variants underlying aHUS and EOMD can prevent or delay 258 
secretion of FH 
32-35
, or severely impair protein function causing reduced FH activity 
22, 25, 33, 36
, leading 259 
to dysregulation of the complement pathway.  However, the impact of rare CFH variants on the 260 
function of the alternative isoform FHL-1 has not previously been investigated. Given the probable 261 
importance of FHL-1 in the EOMD phenotype 
26
, we investigated the expression and secretion of 262 
mutant forms of FHL-1 containing the respective mutations identified in EOMD families A (FHL-263 
1A415f/s), E (FHL-1C431S), and F (FHL-1R127H) compared with full-length wild-type FHL-1 (FHL-1402Y). 264 
Secreted His-tagged recombinant protein was purified from media by affinity chromatography, and 265 
lysates were made from transfected cells for analysis of intracellular expression of recombinant 266 
wildtype or mutant FHL-1.   267 
Western blotting for both the N-terminal His-tag of the recombinant proteins revealed that FHL-1402Y 268 
(wildtype) transfected cells secreted a protein product of expected size (51kDa, slightly larger than 269 
native FHL-1 due to its N-terminal His-tag modification).  However, cells transfected with mutant 270 
plasmids did not secrete a 51kDa protein product at detectable levels within 144 hours of 271 
transfection (Figure 6).  Mock (i.e. - no vector) transfected cells did not secrete any detectable His-272 
tagged protein product, as expected.  Next we investigated whether the mutant proteins were being 273 
expressed but retained intracellularly by examining lysates made from the transfected cells.  274 
Western blot for the His-tag of recombinant mutant and wildtype proteins indicated mutant 275 
proteins were not detectable when analysed using OX23.In comparison, FHL-1402Y (wildtype) was 276 
present in abundance as indicated by the intense ~51kDa band despite equal protein loading as 277 
indicated by SOD2 (~26kDa).  These findings suggest that although wildtype recombinant FHL-1 is 278 
expressed and secreted, mutant forms of FHL-1 are not.  The absence of mutant proteins 279 
intracellularly suggests they are rapidly degraded by the cell soon after synthesis, possibly because 280 
they are unfolded or unstable, rather than synthesized and accumulated within the cell because they 281 















Our findings indicate that the c.1243del, p.(Ala415ProfsTer39) het, c.1291T>A, p.(Cys431Ser) het and 283 
c.380G>A, p.(Arg127His) het variants found to underlie disease in families A, E and F respectively, 284 
could consequently be considered to result from loss-of-function of FHL-1, since the mutant proteins 285 
may be  rapidly degraded upon synthesis and/or not secreted by the cell.  T.  Although beyond the 286 
scope of this study, it may be possible to assess this via the application of inhibitors of degradation 287 
pathways.  The remaining putative EOMD-causing variants: c.350+1G>T het (family B), c.694C>T 288 
p.(Arg232Ter) het (families C and D), and c.619+1G>A het (family G), are also predicted to be loss-of-289 
function variants. This leads us to suggest that haploinsufficiency of FHL-1 is the pathological 290 
mechanism underlying this severe, dominant, early-onset macular drusen phenotype in a subset of 291 
cases(i.e. the identified variants result in reduction in the amount of functional FHL-1 protein 292 
produced which is not sufficient to support the normal function of the retinal pigment epithelium, 293 
leading to disease). 294 
Review of previously reported EOMD mutations 295 
Following on from this hypothesis, we reviewed previously reported cases of EOMD to further define 296 
their mutational mechanisms.  For this analysis we considered literature reports of mutations found 297 
to cause ‘basal laminar drusen’ 
20, 21
, ‘cuticular drusen’ 
23, 37
 and ‘early-onset AMD’ 
22, 24, 25
 in the 298 
absence of kidney disease.  A total of 25 different variants in 29 families have been reported 299 
(Supplementary Data D, available at www.aaojournal.org).  Of these, 19 are non-synonymous 300 
missense variants.  Three variants - c.1198C>A; p.(Gln400Lys) het, c.2850G>C; p.(Gln950His) het, and 301 
c.3628C>T; p.(Arg1210Cys) het -  have each been identified in 2 unrelated families 
23
.  Six different 302 
loss-of-function (i.e. - splice-altering, frameshift or nonsense) variants have also been reported.  One 303 
nonsense variant (c.1222C>T, p.Gln408Ter het) has been identified in two unrelated families 
20
.  Of 304 
the 29 reported EOMD cases, 75.8% (n=22) are due to variants affecting CCP1-7 and impact both FH 305 
and FHL-1. Overall, including the cases reported here, 80.5% (n=29) of reported EOMD-causing 306 
variants (n=36) affect CCP1-7 and thus impact FHL-1 and FH.  Furthermore, 100% of previously 307 















(n=3)) causing EOMD affect CCP1-7.  Of the 15 missense variants affecting CCP1-7, 71.3% (n=11) 309 
have evidence that they prevent secretion or severely reduce protein function.  The remaining four 310 
variants have not been assessed.  In total, 81.8% (n=18) of previously reported EOMD variants 311 
affecting CCP1-7, likely result in haploinsufficiency of FHL-1/FH.  Taking into account the variants 312 
reported herein, this figure increases to 86.2% (n= 25).  Thus, there is considerable evidence in 313 
support of the hypothesis that haploinsufficiency of FHL-1 is the molecular mechanism underpinning 314 
the development of this severe, early-onset phenotype in a proportion of cases.   315 
Two of the other reported missense variants (p.(Pro139Ala) and p.(Arg175Gln)) have supporting 316 
evidence for their pathogenicity in that a different amino acid change at the same position of the 317 
peptide has been reported to cause CFH-related disease with a demonstrated effect on FH serum 318 




 This study identified unrelated families with a history of EOMD associated with deleterious ultra-321 
rare (MAF≤0.0001) heterozygous CFH pathogenic variants. It provides evidence that clinical signs 322 
begin significantly earlier than seen in typical age-related macular degeneration cases; the earliest 323 
reported onset of retinal changes in our cohort is 16 years of age.  The six different variants 324 
identified (Table 1) all localized within CCP2-7 and consequently impact FHL-1 and FH. FHL-1 is a 325 
short form of FH that retains all of the regulatory functions of the full-length protein that has been 326 
suggested to be the predominant regulator of complement in BrM, the extracellular matrix (ECM) 327 
layer that lies beneath the human retina, and the intercapillary septa 
26
.  We propose that lost or 328 
reduced function of FHL-1 leads to dysregulation of complement turnover in the ECM of Bruch’s 329 
membrane and choriocapillaris, and may be the mechanism driving development of EOMD in these 330 




The identified putative splice-altering and nonsense variants are likely to result in haploinsufficiency 333 















differing effects on the two isoforms. In FH (NM_000186), this frameshift is predicted to undergo 335 
NMD while in FHL-1 (NM_001014975), this same single base pair deletion is predicted to result in a 336 
frameshift within the penultimate exon that is likely to escape NMD, creating a stop codon 47 amino 337 
acids downstream [p.(Ala415ProfsTer47)] and resulting in an extension of the normal 449 amino acid 338 
product by 13 amino acids, as well as loss of its unique four amino acid C-terminal tail which is 339 
known to have a role in the proteins binding to pro-inflammatory monomeric C-reactive protein 
40
.  340 
Predicting the impact of missense variants on protein function is challenging, particularly for the CFH 341 
gene 
33
.  Both of the missense variants, p.(Cys431Ser) and p.(Arg127His), as well as the 342 
p.(Ala415ProfsTer47) frameshift variant, were investigated in vitro.  By expressing these 343 
recombinant mutant FHL-1 proteins we have demonstrated that none of the three allowed the 344 
production of a secreted FHL-1 product.  We suggest that all three variants may also result in loss of 345 
protein function.  The CFH p.(Cys431Ser) variant replaces the highly conserved, third cysteine 346 
residue of the 7
th
 CCP domain.  One of the defining characteristics of a CCP domain is the presence of 347 
two disulphide bonds with the cysteine-cysteine pattern of C1-C3 and C2-C4, therefore this amino acid 348 
substitution likely disrupts the structure and function of CCP7, and results in a free cysteine that may 349 
covalently interact with surrounding residues.  Functional characterization of a different amino acid 350 
substitution at the same position of the peptide, p.(Cys431Tyr), showed that it decreased stability of 351 
the recombinant FH 
41
.  Moreover, mass spectrometry analysis of plasma from the affected patient 352 
found that the protein product of the mutated allele was not present, suggesting that the change 353 
prevents secretion and/or the mutated protein is rapidly degraded 
41
The CFH p.(Arg127His) 354 
substitution alters CCP2, in a region of FH/FHL-1 previously shown to be important for C3b binding 355 
and co-factor activity 
35
.  In vivo investigations have shown that p.(Arg127His) results in retention of 356 
mutant full-length FH in the endoplasmic reticulum (ER) of cultured patient fibroblasts 
35
.Review of 357 
29 CFH mutations previously reported as the underlying cause of EOMD (‘basal laminar drusen, 358 
‘cuticular drusen’, and ‘early-onset AMD’), found that 75.8% impact FHL-1 as well as FH.  This figure 359 















reported nonsense, splice-altering and frameshift variants (5 by this study, 7 reported previously in 361 
the literature) fall within CCP1-7.  Furthermore, all missense substitutions (n =10) affecting CCP1-7, 362 
which have been evaluated in vitro, have been found to prevent secretion or result in loss of protein 363 
function.  Consequently, at least 81% of reported EOMD variants result in loss of protein function, 364 
strongly supporting the hypothesis that haploinsufficiency of FHL-1 is one important mechanism 365 
underpinning the development of drusen in early adulthood. The contribution of AMD-related loci to 366 
EOMD if any, remains elusive but is an important area for future research.  Moreover, identification 367 
of higher numbers of affected individuals or families would likely be required to associate 368 
demographics such as age at onset and severity with AMD risk alleles in this subgroup of patients.   369 
Strict control of innate immunity at BrM is critical for maintaining normal homeostasis and health of 370 
the retina.  It is becoming increasingly apparent that one of the main pathological characteristics of 371 
AMD is inflammation of the central retina and consequential particulate accumulation (drusen 372 
development), cellular damage and subsequent loss of vision as a result of complement 373 
dysregulation 
42
. Factor H, and almost certainly FHL-1, are the only components of the complement 374 
system known to downregulate alternative pathway activation on host extracellular matrix and self-375 
surfaces via interaction with binding partners and co-factors 
12, 39
.  There is increasing evidence that 376 
the eye synthesises complement pathway components locally 
5, 43, 44
, and the importance of 377 
functional FHL-1 at the retina is becoming ever more apparent 
26, 27, 40
.   378 
It is known that FHL-1 is the only isoform that can passively diffuse across Bruch’s membrane; FH 379 
cannot because of its large size 
26
.  FHL-1 is immobilized in Bruch’s membrane and the ECM of the 380 
choriocapillaris by interaction with heparan sulfate via its glycosaminoglycan (GAG)-binding site in 381 
CCP7.  In this way, FHL-1 functions to protect the ECM from complement activation
26
.  The Y402H 382 
polymorphism has been shown to affect the function of FHL-1; the 402H variant reduces FHL-1 383 
binding to heperan sulphate
26
.  According to the GnomAD database, 44.08% of individuals from all 384 
populations (ALL) (42.6% in the European (non-Finnish) population (EUR)) are heterozygous for the 385 















402H variant are at a two-fold increased risk of AMD, whereas those that are homozygous have a 387 
greater than five-fold increased risk
4
.  Studies have shown that while the AMD-associated Y402H 388 
allele does not alter FH protein conformation, nor does it alter FH levels in blood, it does result in 389 
decreased ability of FHL-1 to bind heparan sulfate
26
: any changes to FH binding to GAGs appears 390 
minimal due to this larger protein’s second GAG binding site.
 
 Furthermore, recent work has shown 391 
that the Y402H polymorphism has a more pronounced effect on FHL-1 binding of Pentraxin-3 (PTX3) 392 
- an inflammation-associated protein that binds FH at CCP7 and CCP19-20 and serves to increase 393 
interaction of FH with apoptotic cells for iC3b opsonisation – than it does on FH binding of PTX3, 394 
most likely because it affects the only PTX3 binding site within FHL-1
40
.  Taken together, this 395 
evidence suggests that loss of FHL-1 expression or function would have a detrimental impact on 396 
regulation of the complement system in the retina.  397 
Previous publications that have identified rare, highly penetrant CFH mutations in association with 398 
EOMD have focussed on the location of mutations within the FH protein with respect to known 399 
functions of domains
23, 37
.  However, it is now recognised that FHL-1 is the predominant regulator of 400 
the complement pathway within BrM and the intercapillary septa
26
.  FH and FHL-1 both negatively 401 
regulate the alternative complement pathway by competing for binding to C3b with factor B (FB) to 402 
govern the removal of immune complexes and pathogens, and modulate adaptive immunity.  They 403 
also serve as co-factors for factor-I (FI) cleavage of C3b into its haemolytically inactive state, iC3b. 404 
We suggest that pathogenic variations in FHL-1 resulting in loss / impairment of function are an 405 
important cause of EOMD in the vast majority of cases.   406 
There exists a well-recognised genotype-phenotype correlation with respect to CFH variants and 407 
disease; with variants affecting CCP1-4 and CCP6-8 mainly causing eye disease, whereas those 408 
affecting CCP19-20 cause kidney disease
17
.  This is supported by research that has shown the GAG-409 
binding site in CCP7 demonstrates selectivity towards heparan sulfates in Bruch’s membrane and the 410 
choriocapillaris, whereas the CCP19-20 region preferentially binds heparan sulfates in the glomerular 411 
basement membrane of the kidneys
12, 47















explained by current understanding of the function of FH and FHL-1, representing an important area 413 
for future research.  414 
In conclusion, rare, deleterious mutations in CFH resulting in haploinsufficiency of FH/FHL-1 are an 415 
important and under-recognised cause of dominant EOMD.  Identification of CFH variants underlying 416 
EOMD has important consequences for clinical care, allowing genetic testing of other family 417 
members and counselling where appropriate; the identification of the underlying molecular cause 418 
can allow the provision of more accurate prognostic information, particularly where variants are 419 





Furthermore, with complement modulating therapeutics being under development for AMD such 421 
genetic analyses may identify subsets of patients who may benefit from these new treatments.  The 422 
impact of variants on the expression and/or function of FHL-1 have not previously been considered 423 
for EOMD, and we propose that this truncated form of FH plays a crucial role in EOMD and 424 
potentially AMD.  Identification of further mutations causing the rare, genetically heterogeneous 425 
EOMD phenotype will lead to a better understanding of disease pathogenesis. 426 
Figure Legends 427 
Figure 1: Fundus autofluorescence imaging in patients with EOMD with rare CFH variants.  a-b) 428 
Patient A:II.3 aged 51 years showing drusen at the macula and extending beyond the vascular 429 
arcades; c-d) Patient A:II.1 aged 49 years with drusen extending outside the macular region (c); e-f) 430 
Patient B:II.2 aged 89 showing drusen and  retinal atrophy at the macula and in the nasal retina in 431 
both eyes; g-h) Patient B:I.1 aged 61 years with bilateral macular drusen and drusen nasal to the 432 
optic discs; i-j) Patient C:I.2 aged 64 years showing loss of central signal consistent atrophy, drusen 433 
are present around the atrophy and optic nerve; k-l) Patient D:I.7 aged 26 years showing geographic 434 
atrophy and large colloidal macular drusen; m-n) Patient E:II.2 aged 53 years showing 435 
hypoautofluorescence centrally due to geographic atrophy with a surrounding ring of  436 















sparse temporal drusen; q-r) Patient G:III.7 aged 66 showing scattered macular drusen and patches 438 
of geographic atrophy.   439 
Figure 2: Protein schematic of FH and FHL-1.  Schematic diagram of FH and FHL-1 detailing protein 440 
domains and corresponding amino acid positions with locations of mutations identified in our EOMD 441 
cohort. Factor H (FH) contains 20 CCP domains (top), whereas FHL-1 encodes 7 CCP domains 442 
(bottom) FH CPP 1-7. Regions associated with C3b binding are indicated by adjacent red bars; co-443 
factor activity by the green bar; heparin binding sites by blue bars; and sialic acid binding site by the 444 
purple bar.  The locations of mutations identified by this study are indicated by grey-dashed lines. 445 
Bracketed letter following mutation nomenclature indicates the study ID of the family in which the 446 
mutation was identified.  447 
Figure 3 Expression of wild type and mutant FHL-1 in transfected HEK293 cells.  HEK293 cells were 448 
stably transfected with His-tagged wildtype pcDNA3.1-FHL-1 (FHL-1Y402) or one of three mutant 449 
constructs (FHL-1C431S, FHL-1R127H, FHL-1A415f/s) as indicated at the top of each gel image, to assess the 450 
effect of the identified variants on protein expression and secretion over 144hours.  Recombinant 451 
proteins purified from culture media (secreted) and cell lysates (intracellular) were subjected to SDS-452 
PAGE and transferred to a nitrocellulose membrane.    Figure shows Western blot results from 453 
analysis of experimental samples for OX23.  Presence of a band indicates presence of recombinant 454 
FHL-1.  Cells transfected with mutants did not secrete a detectable FHL-1 product (~51kDa) in 455 
comparison to wildtype FHL-1.  Mock (no DNA) transfected cells did not produce an FHL-1 product, 456 
as expected.  Analysis of cell lysates found no accumulation of mutant recombinant proteins 457 
intracellularly but wildtype recombinant FHL-1 was found to be present. SOD2 (~26kDa) indicates 458 
equal sample loading of cell lysates. 459 
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Table 1:- Phenotypic and genetic findings in early-onset macular drusen patients with CFH mutations.  Table details study ID, age at most recent exam, retinal and extra-ocular phenotype (if any), 














Visual Acuity (Snellen 
(LogMar)) 










early-onset drusen, RPE mottling at 






Normal and grossly 
symmetrical light adapted 
response.  Slightly reduced 
dark adapted response in RE 
suggesting asymmetrical rod 
involvement. 




Bilateral widespread drusen, 
concentrated temporal to and 
within the macular 
6/3.8-1 6/3.8-1 
Normal and grossly 
symmetrical light adapted 
response.  Slightly reduced 
dark adapted response in LE 






Bilateral, symmetrical, outer retinal 
atrophy, multiple drusen, severe 
visual loss 
- - NA 




Multiple drusen bilaterally, pattern 
similar to that seen in affected 
mother, II.1 
6/6 6/6 NA 
C:I.2/F/54 64 Yes 
Bilateral drusen surrounding central 
atrophy and extending into the 
arcades.  Patchy atrophy in the 
peripheral retina with reticular and 
drusenoid features. 


















D:I.7/F/26  50 
Yes 







Bilateral retinal drusenoid 
dystrophy with CNV and significant 
scarring 
1/60 6/24 NA 
E:II.2/F/50 52 
Yes 
Early onset macula dystrophy, 





Extinguished PERGs, normal 
EOG, normal ERG; 







Bilateral small, sparse drusen at the 
maculae. 
6/4 6/7.5 NA 
F:II.2/F/46 54 Yes 
Isolated sparse drusen within the 














G:III.7/F/45 66 Yes 
Bilateral large, sparse white/yellow 
drusen at the maculae, nasal to the 
disc and the surrounding arcades. 









NA c.619+1G>A het 3-4 - 
†Age at onset is defined as age at which retinal changes were first detected; Y:Years; M: Male; F:Female; VA: visual acuity; NA: information not available; PED: pigment epithelial detachment; LE: left eye; RP: retinitis 
pigmentosa; EDT: Electrodiagnostic Testing; PERGs: Pattern electroretinograms; EOG: Electrooculogram; ERG: Electroretinogram; CNV: Choroidal neovascularisation *A positive family history is defined as another blood relative 


















































Loss-of-function mutations in CFH that impact FHL-1, the main regulator of the complement 
pathway in Bruch’s membrane, cause early-onset macular drusen providing a novel mechanistic 
insight into macular disease that could inform AMD pathogenesis. 
 
